IP Library Granted Patent US 10,532,992
Granted Patent B2
US 10,532,992 · App. 16/005,160 · Granted Jan 14, 2020

Prodrugs of urolithins and uses thereof

Inventors: Christopher Rinsch (Morges, CH); Rune A. Ringom (Uppsala, CH)
Assignee: Amazentis SA
C07D311/80A61K31/366A61K31/4025A61K45/06C07D405/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,532,992
App. No.
16/005,160
Granted
Jan 14, 2020
Kind
B2
Abstract

The invention provides compounds of formula (I) or salts thereof: wherein: A, B, C, D, W, X, Y and Z are as defined in the specification, and at least one of A, B, C, D, W, X, Y and Z is OR 1 ; each R 1 being independently H or C(═O)R 2 , and at least one R 1 group being C(═O)R 2 ; where each R 2 is selected from: CHR 3 NHR 4 , where R 4 is H and R 3 is a group selected from CH 3 , CH 2 CH(CH 3 ) 2 , CH(CH 3 )CH 2 CH 3 , CH 2 Ph, CH 2 -3-(1H-indole), CH 2 CH 2 SCH 3 , CH 2 OH, CHOHCH 3 , CH 2 SH, CH 2 SeH and CH 2 PhpOH, wherein said R 3 group can optionally be substituted by one or more groups selected from halogen, cyano, nitro, OR A or C 1 -C 4 alkyl; or R 3 and R 4 together with the C and N atoms to which they are attached form a 5-membered heteroalkyl ring, wherein said heteroalkyl ring can optionally be substituted by one or more groups selected from halogen, cyano, nitro, OR A or C 1 -C 3 alkyl, wherein R A is C 1 -C 4 alkyl optionally substituted with one or more halogen, cyano or nitro groups. The compounds are effective pro-drugs for urolithins and they enable the ready delivery of urolithins to the site in the digestive tract where they can be absorbed into the body.

Claims (32)

1. A compound of formula (I) or a salt thereof:

wherein:

A, B, C, W, X, and Y are H;

D is H or OR 1 ;

Z is H or OR 1 ;

each R 1 is independently H or C(═O)R 2 , and at least one R 1 group is C(═O)R 2 ;

each R 2 is independently CHR 3 NHR 4 ;

R 4 is H;

R 3 is independently a group selected from CH 3 , CH 2 CH(CH 3 ) 2 , CH(CH 3 )CH 2 CH 3 , CH 2 Ph, CH 2 -3-(1H-indole), CH 2 CH 2 SCH 3 , CH 2 OH, CHOHCH 3 , CH 2 SH, CH 2 SeH, and CH 2 PhpOH, wherein said R 3 group is optionally substituted by one or more groups selected from halogen, cyano, nitro, OR A , and C 1 -C 4 alkyl; or R 3 and R 4 taken together with the C and N atoms to which they are attached form a 5-membered heteroalkyl ring, wherein said heteroalkyl ring is optionally substituted by one or more groups selected from halogen, cyano, nitro, OR A or C 1 -C 3 alkyl; and

R A is C 1 -C 4 alkyl optionally substituted with one or more halogen, cyano or nitro groups; provided that at least one of D and Z is OR 1 .

2. The compound of claim 1 , wherein D is OR 1 .

3. The compound of claim 1 , wherein Z is OR 1 .

4. The compound of claim 1 , wherein D and Z are OR 1 .

5. The compound of claim 1 , wherein R 3 is CH 3 , CH 2 CH(CH 3 ) 2 , or CH(CH 3 )CH 2 CH 3 ; or R 3 and R 4 taken together with the C and N atoms to which they are attached form an unsubstituted 5-membered heteroalkyl ring.

6. The compound of claim 4 , wherein R 3 is CH 3 , CH 2 CH(CH 3 ) 2 , or CH(CH 3 )CH 2 CH 3 ; or R 3 and R 4 taken together with the C and N atoms to which they are attached form an unsubstituted 5-membered heteroalkyl ring.

7. The compound of claim 1 , wherein R 3 is CH 3 , CH 2 CH(CH 3 ) 2 , or CH(CH 3 )CH 2 CH 3 .

8. The compound of claim 4 , wherein R 3 is CH 3 , CH 2 CH(CH 3 ) 2 , or CH(CH 3 )CH 2 CH 3 .

9. The compound of claim 1 , wherein the compound is:

10. The compound of claim 1 , wherein the compound is:

11. The compound of claim 1 , wherein the compound is:

12. The compound of claim 1 , wherein the compound is

13. A pharmaceutical composition comprising a compound of claim 1 ; and a carrier.

14. The pharmaceutical composition of claim 13 , wherein the compound is:

15. The pharmaceutical composition of claim 13 , wherein the compound is:

16. The pharmaceutical composition of claim 13 , wherein the compound is:

17. The pharmaceutical composition of claim 13 , wherein the compound is

18. A food, beverage or dietary supplement containing a compound of claim 1 .

19. The food, beverage or dietary supplement of claim 18 , which is in the form of a food additive, a food ingredient, a functional food, a medical food, a nutraceutical, a food supplement, a functional beverage, or a gel.

20. The food, beverage or dietary supplement of claim 18 , wherein the compound is:

21. The food, beverage or dietary supplement of claim 18 , wherein the compound is:

22. The food, beverage or dietary supplement of claim 18 , wherein the compound is:

23. The food, beverage or dietary supplement of claim 18 , wherein the compound is

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2018
From: RINSCH, CHRISTOPHER L.
To: AMAZENTIS SA
Reel/Frame 046053/0352 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2018
From: RINGOM, RUNE ANDREAS
To: ONTARGET CHEMISTRY AB
Reel/Frame 046053/0355 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2018
From: ONTARGET CHEMISTRY AB
To: AMAZENTIS SA
Reel/Frame 046053/0377 →
Priority Claims (1)
GB 1323008.1 · Dec 24, 2013 · national
Continuity (2)
Continuation 15107467
Related Publication 20190010138A1 · Jan 10, 2019
Cited By (6)
US 12,351,567 US 12,358,884 US 12,473,269 US 12,544,358 US 12,576,064 US 12,576,065